Targeted therapies: disappointing outcomes for anti-VEGF therapy

Comment

Lisa Richards. Nat Rev Clin Oncol. 2011.

. 2011 Mar 8;8(4):194.

doi: 10.1038/nrclinonc.2011.28.

No abstract available

Comment on

Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Ranpura V, Hapani S, Wu S. Ranpura V, et al. JAMA. 2011 Feb 2;305(5):487-94. doi: 10.1001/jama.2011.51. JAMA. 2011. PMID: 21285426
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
Kindler HL, Ioka T, Richel DJ, Bennouna J, Létourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E. Kindler HL, et al. Lancet Oncol. 2011 Mar;12(3):256-62. doi: 10.1016/S1470-2045(11)70004-3. Lancet Oncol. 2011. PMID: 21306953 Clinical Trial.